The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
12 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,094,511 in first-year total cost, median $423,400.
Most frequent study sections
- Drug Discovery for the Nervous System Study Section[DDNS]12
Most frequent institutions
- UNIVERSITY OF CALIFORNIA LOS ANGELES3
- PURDUE UNIVERSITY2
- UNIV OF NORTH CAROLINA CHAPEL HILL2
- DARTMOUTH COLLEGE1
- EMORY UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Identification of CNS-Penetrant Tryptophan 2,3-Dioxygenase Degrading Ligands1R21AG078775-01 | ALTMAN, RYAN ALIU, AIMIN | PURDUE UNIVERSITY, IN | $235,901 | DDNS |
| 2021 | Use of Bioinformatics and Genetics to Identify a New Class of Drugs for Neurological Disease1R21AG072142-01 | MYERS, SCOTT JAMES | EMORY UNIVERSITY, GA | $425,269 | DDNS |
| 2021 | Screening for enhancers of secreted clusterin (sCLU) and evaluation in AD models1R21AG072150-01 | JOHN, VARGHESE | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $423,400 | DDNS |
| 2021 | Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels1R21AG063007-01A1 | JOHN, VARGHESE | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $423,400 | DDNS |
| 2021 | Negative allosteric modulators of the D3 dopamine receptor as therapeutic leads for substance use disorders1UG3DA050820-01A1 | FRANKOWSKI, KEVIN J. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $233,250 | DDNS |
| 2021 | Small molecule inhibitors of hyperphosphorylated tau aggregation and cytotoxicity for the development of Alzheimer’s therapeutics1R21AG070447-01A1 | FORTIN, JESSICA | PURDUE UNIVERSITY, IN | $220,488 | DDNS |
| 2021 | D1 dopamine receptor positive allosteric modulators as a practical treatment for cognitive decline1R21AG068833-01A1 | FRANKOWSKI, KEVIN J. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $194,375 | DDNS |
| 2020 | Chimeric antigen receptor T regulatory cells as therapy for Alzheimer's Disease1R21AG067971-01 | SENTMAN, CHARLES L. | DARTMOUTH COLLEGE, NH | $451,000 | DDNS |
| 2020 | Novel Wnt activators for Alzheimer's disease therapy1R21AG065653-01A1 | LI, YONGHE | MAYO CLINIC JACKSONVILLE, FL | $430,375 | DDNS |
| 2020 | Screening for SORLA enhancers and evaluation in AD models1R21AG067461-01 | JOHN, VARGHESE | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $429,000 | DDNS |
| 2020 | Development of Novel ERRa Selective Agonists as Chemical Probes for the Potential Treatment of Alzheimer's Disease1R21AG065657-01 | ELGENDY, BAHAA | ST. LOUIS COLLEGE OF PHARMACY, MO | $426,553 | DDNS |
| 2020 | Low-Efficacy Dopamine D4 Receptor Partial Agonists for Cocaine Addiction1R21DA050896-01A1 | BOATENG, COMFORT AHENKANKECK, THOMAS MCGOWAN | HIGH POINT UNIVERSITY, NC | $201,500 | DDNS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.